Sat.Feb 25, 2023 - Fri.Mar 03, 2023

article thumbnail

How to find and take part in paid clinical trials

Antidote

Participating in a clinical trial has many benefits, including working with condition specialists, getting access to personalized medical care, and helping science move forward — but did you know that some clinical trials offer compensation, as well?

article thumbnail

Modern Coal Miners Have Higher Death Rates From Lung Diseases Than Their Predecessors

NIOSH Science Blog: Drugs

Coal mine dust causes a range of lung diseases, collectively called coal mine dust lung diseases. Examples include coal workers’ pneumoconiosis (CWP, a dust-induced scarring lung disease commonly called black lung), chronic obstructive pulmonary disease (COPD), and lung function impairment. All of these cause substantial morbidity (illness) and mortality (death) among affected coal miners.[1–5] Most attention in the U.S. has focused on CWP, especially its most severe stage called progressive mas

Disease 90
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Which pharmaceutical companies have the most drug patents in Serbia?

Drug Patent Watch

This chart shows the pharmaceutical companies with the most patents in Serbia. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is… The post Which pharmaceutical companies have the most drug patents in Serbia? appeared first on DrugPatentWatch - Make Better Decisions.

article thumbnail

What a Technology-First Approach Really Means for Your Patient Support Program

Drug Channels

Today’s guest post comes from Jan Nielsen, Patient Solutions Division President at AssistRx. Jan discusses digital hubs and the benefits they offer both patients on specialty therapies and their health care providers. To learn more, download AssistRx's free 61-page eBook: Specialty Drug Patient Support Programs: 2022 Progress Report. Read on for Jan’s insights.

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

A covalent BTK ternary complex compatible with targeted protein degradation

Covalent Modifiers

James Schiemer, Andrew Maxwell, Reto Horst, Shenping Liu, Daniel P. Uccello, Kris Borzilleri, Nisha Rajamohan, Matthew F. Brown & Matthew F. Calabrese Nat Commun 14 , 1189, 2023 [link] Targeted protein degradation using heterobifunctional chimeras holds the potential to expand target space and grow the druggable proteome. Most acutely, this provides an opportunity to target proteins that lack enzymatic activity or have otherwise proven intractable to small molecule inhibition.

article thumbnail

Multiple Myeloma Research Benefits from Living Model SLR: A Case Study

Cytel

The speed of scientific discovery has been outpacing the ability of researchers to accumulate and integrate constantly evolving new insights into systematic literature reviews (SLRs). This gets compounded by obstacles to accessing the newest publications. For one pharmaceutical company looking to evaluate the potential impact of surrogate endpoints on long-term clinical outcomes in multiple myeloma, an SLR was needed in just two months for the research to support reimbursement submissions.

More Trending

article thumbnail

Defining Organoids: Exploring Their True Characteristics and Practical Uses

Crown Bioscience

The use of more clinically relevant preclinical models can help to reduce anticancer drug attrition rates by providing a better understanding of the safety, efficacy, and mechanism of a drug candidate, which can help inform downstream decisions.

Drugs 52
article thumbnail

Ten Women that Changed the World with their Contributions to STEM

BenchSci

Diversity, equity, and inclusion are important to us at BenchSci and as a part of our DEI journey we are committed to learning about, celebrating, and amplifying the voices and accomplishments of people from diverse backgrounds.

52
article thumbnail

The Product Launch Learning Journey with Jennifer Troiano

ACTO

Launching a new product in the Life Sciences industry is no easy feat. It requires a significant investment of time, resources, and expertise and can ultimately make or break a company’s success. However, despite the high stakes involved, success is far from guaranteed. The lack of a clear blueprint for success in product launches can leave teams feeling lost and unsure how to proceed.

article thumbnail

New patent expiration for Dialysis Sups drug NORMOCARB HF 25

Drug Patent Watch

Annual Drug Patent Expirations for NORMOCARB+HF+25 Normocarb Hf 25 is a drug marketed by Dialysis Sups and is included in one NDA. There is one patent protecting this drug. This… The post New patent expiration for Dialysis Sups drug NORMOCARB HF 25 appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 74
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

Identifying the Triggers and Causes of Eczema in Adults

Olympian Clinical Research

While many people think of eczema as an issue that mainly affects children, the skin condition may also manifest later in life. The triggers and causes of eczema in adults may vary from person to person. If you suffer from dry, itchy skin and red rashes on your body, then chances are you have a form of eczema known as atopic dermatitis ( AD ). When AD develops after your 18th birthday, it is known as adult-onset atopic dermatitis.

article thumbnail

Experiencing the Festival of Genomics & Biodata 2023

sptlabtech

On January 25th I had the pleasure of attending the Festival of Genomics and Biodata that returned as an in-person event after being held virtually for two years. It truly returned with a bang, bigger and busier than ever, with eight streams of scientific talks, over 90 exhibitors, and over 4000 attendees. It was a vibrant event that attracted a broad range of genomics-minded delegates from academia, industry, and public sector.

article thumbnail

Metabolism of five membered nitrogen containing heterocycles

Metabolite Tales Blog

Metabolism of nitrogen containing five-membered aromatic heterocycles nitrogen containing five membered aromatic heterocycle Highlighting trends in oxidation and glucuronidation of these ring systems in drugs By Samuel Coe Five membered nitrogen containing aromatic heterocycles are commonly used in medicinal chemistry for multiple reasons, including reduced lipophilicity compared to phenyl groups, increased metabolic stability and ease of substitution.

article thumbnail

Which pharmaceutical companies have the most SPCs in Italy?

Drug Patent Watch

This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Italy. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating… The post Which pharmaceutical companies have the most SPCs in Italy? appeared first on DrugPatentWatch - Make Better Decisions.

article thumbnail

Deliver Fast, Flexible Clinical Trial Insights with Spotfire

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

article thumbnail

ChEMBL 32 is released!

The ChEMBL-og

We are pleased to announce the release of ChEMBL 32! This release of ChEMBL comes with a complete update of drug and clinical candidate information, the addition on a Natural Product likeness score and a harmonization of Journal Name abbreviations according to NLM standards. This version of the database, prepared on 26/01/2023 contains: 2,354,965 compounds (of which 2,327,928 have mol files) 2,995,433 compound records (non-unique compounds) 20,038,828 activities 1,536,903 assays 15,139 targets 8

article thumbnail

Histone deacetylases (HDACs): erasers of epigenetic marks | BMG LABTECH

BMG Labtech

The discovery of an enzyme that removes acetyl groups from histone dates to 1969 when Inoue and Fujimoto discovered histone deacetylase (HDAC) activity in calf thymus extract. 1 This finding, which arose from curiosity-driven research, opened new areas of enquiry, led to a better understanding of epigenetics, and launched a host of clinical investigations for new drugs to treat cancer, inflammation, and neurological diseases.

FDA 52
article thumbnail

Frontiers for Young Minds

keypoint

Today’s Open Access Spotlight goes to Frontiers for Young Minds , a non-profit science journal for kids, BY kids! That’s right, a publication where kids are the reviewers of the latest scientific research. Each article is written by top researchers, including Nobel Prize winners, and is then reviewed by young students aged 8-15. Working with the guidance of Science Mentors locally in 65 countries, Young Reviewers ensure that everything is accessible and engaging for their peers.

Science 52
article thumbnail

New patent expiration for Msd Sub drug ZOLINZA

Drug Patent Watch

Annual Drug Patent Expirations for ZOLINZA Zolinza is a drug marketed by Msd Sub Merck and is included in one NDA. It is available from one supplier. There are nine… The post New patent expiration for Msd Sub drug ZOLINZA appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

Clinical Data Like You´ve Never Seen It Before: Why Spotfire Is the Leading Tool for Clinical Analytics

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

article thumbnail

Build It & They Will Come: Momentum Building For CBL-B Inhibition

LifeSciVC

By Jonathan Montagu, CEO of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC The phrase ‘build it and they will come’ dates all the way back to the Old Testament, and in more recent times has been romanticized in movies like Field of Dreams , but the concept also holds true in many areas of science. Even good ideas are met with healthy skepticism for the practical and technical limitations of being able to effectively test a hypothesis.

article thumbnail

Transformational Relationships: How a Consultative Approach from a CRO Adds Value to Your Development Program

Conversations in Drug Development Trends

The advent of outsourcing in clinical research came about in the 1980s based on transactional business-to-business interactions, which focused on the completion of specific development tasks. Through the 1990s, sponsors required a more sophisticated offering from CROs who were required to master fundamental study operations and processes, offering scalability to sponsors’ operations departments.

article thumbnail

Predictive Oncology partners with Cvergenx to create new genomics-based A.I. radiation therapy

Predictive Oncology

Proactive Investor’s Natalie Stoberman met with Raymond F. Vennare, CEO of Predictive Oncology, and Javier Torres-Roca, MD, Co-Founder and CEO of Cvergenx, Inc., to discuss a strategic partnership to create the first-ever genomics-based approach to precision radiation therapy and drug discovery using artificial intelligence. Click here to view the interview and learn more about how this powerful collaboration will leverage Predictive Oncology’s drug discovery, artificial intelligence and machin

article thumbnail

Which drugs have supplementary protection certificates in the most countries?

Drug Patent Watch

This chart shows the drugs with the most supplementary protection certificates (SPCs). SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating for the long… The post Which drugs have supplementary protection certificates in the most countries? appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

Development of a Covalent Inhibitor of c-Jun N-Terminal Protein Kinase (JNK) 2/3 with Selectivity over JNK1

Covalent Modifiers

Wenchao Lu, Yao Liu, Yang Gao, Qixiang Geng, Deepak Gurbani, Lianbo Li, Scott B. Ficarro, Cynthia J. Meyer, Dhiraj Sinha, Inchul You, Jason Tse, Zhixiang He, Wenzhi Ji, Jianwei Che, Audrey Y. Kim, Tengteng Yu, Kenneth Wen, Kenneth C. Anderson, Jarrod A. Marto, Kenneth D. Westover, Tinghu Zhang, and Nathanael S. Gray Journal of Medicinal Chemistry 2023 DOI: 10.1021/acs.jmedchem.2c01834 The c-Jun N-terminal kinases (JNKs) are members of the mitogen-activated protein kinase (MAPK) family, which inc

article thumbnail

Accelerating Cancer Drug Development for Children and Adolescents

Crown Bioscience

Significant progress has been made in the treatment of pediatric cancers, with the 5-year survival rate for children with cancer overall in high-income countries currently at ~80%. Despite this progress, there are still major unmet needs in this patient population. The 5-year survival rate for children with cancer in middle- and low-income countries are ~55% and ~40%, respectively, and survival prospects for several pediatric cancers are still very poor.

article thumbnail

Honoring Clinical Trailblazers: 2023 Video Series

Advarra

This February, Advarra’s “Honoring Clinical Trailblazers” video series paid tribute to the outstanding achievements of four pioneering African American physicians who defied the odds to make significant contributions to the field of medicine. These physicians faced enormous challenges due to their race, gender, and societal barriers, but their passion for helping others and their unwavering commitment to advancing medical knowledge led to groundbreaking discoveries and changes,

article thumbnail

New patent for Jazz Pharms drug XYREM

Drug Patent Watch

Annual Drug Patent Expirations for XYREM Xyrem is a drug marketed by Jazz Pharms and is included in one NDA. It is available from two suppliers. There are eight patents… The post New patent for Jazz Pharms drug XYREM appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

Before Clinical Trials: The Long Game of Rare Disease Research

Conversations in Drug Development Trends

95% of rare diseases don’t have a treatment approved and won’t anytime soon. Uplifting Athletes (UA) is on a mission to change that. Back in 2010, Rob Long was a 22-year-old football player at Syracuse University on the path towards his dream career of becoming a punter in the NFL. But just a few months before his college graduation and the start of his career, Rob’s dreams fell to pieces.

article thumbnail

How Antidote recruits for rare disease trials

Antidote

Rare Disease Day occurs every year on the last day of February, and is aimed at raising awareness and creating change for the 300 million individuals across the globe living with a rare disease.

Disease 52
article thumbnail

NIH 2023 Data Management and Sharing Policy: What you Need to Know

Advarra

In an effort to accelerate the sharing of biomedical research results, the National Institutes of Health (NIH) issued its finalized Data Management and Sharing (DMS) policy , effective January 25, 2023. The policy is fundamentally intended to promote and expedite the “translation of research results into knowledge, products, and procedures to improve human health.

article thumbnail

Tablet dosed drug patent expirations by year

Drug Patent Watch

This chart shows the patent expirations for tablet dosed drugs over the next decade. The term of drug patents varies. The basic term for a patent is 20 years from… The post Tablet dosed drug patent expirations by year appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52
article thumbnail

How Drug Development CMC Works 

DS in Pharmatics

When pharmaceutical companies develop a new drug product for the market, there are many different steps a potential product must go through to determine and control its safety, manufacturability, effectiveness and reliability. These processes, and all activities within, are known as chemistry, manufacturing, and controls (CMC).

article thumbnail

Drug Channels News Roundup, February 2022: Mark Cuban vs. PBMs, MDs on Humira Biosimilars, States vs. PBMs, 340B Transparency, and Health Insurer Humor (?)

Drug Channels

The era of artificial-intelligence chatbots has arrived! I am pleased to report that this month’s Drug Channels news roundup was most definitely not written by ChatGPT. No promises about future articles. (See our forecast to the right.) In this issue: Mark Cuban explains his anti-PBM strategy What physicians think about Humira biosimilars States go after PBMs HHS is confused about 340B transparency Plus, The Onion tests your knowledge of United Healthcare’s policies.

article thumbnail

Science2Startup 2023: Innovation And Entrepreneurship

LifeSciVC

Science2Startup (S2S) is back! In April 2020, we were planning the 3 rd annual S2S conference for university-focused biotech entrepreneurship – but it was unfortunately scuttled by COVID. A subsequent event in 2021 was also precluded by the pandemic. But as we all regain some normalcy, so too with S2S. We’re relaunching the event on May 3, 2023 at the Broad Institute.

Science 40